Early, very high-titre convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19 (COVIC-19): protocol for a randomised, open-label trial

INTRODUCTION: COVID-19 convalescent plasma (CCP) is a possible treatment option for COVID-19. A comprehensive number of clinical trials on CCP efficacy have already been conducted. However, many aspects of CCP treatment still require investigations: in particular (1) Optimisation of the CCP product,...

Descripción completa

Detalles Bibliográficos
Autores principales: Desmarets, Maxime, Hoffmann, Simone, Vauchy, Charline, Rijnders, Bart J A, Toussirot, Eric, Durrbach, Antoine, Körper, Sixten, Schrezenmeier, Eva, van der Schoot, C Ellen, Harvala, Heli, Brunotte, Gaëlle, Appl, Thomas, Seifried, Erhard, Tiberghien, Pierre, Bradshaw, Daniel, Roberts, David J, Estcourt, Lise J, Schrezenmeier, Hubert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Infectious Diseases
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10151238/
https://www.ncbi.nlm.nih.gov/pubmed/37105693
http://dx.doi.org/10.1136/bmjopen-2022-071277

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10151238/
https://www.ncbi.nlm.nih.gov/pubmed/37105693
http://dx.doi.org/10.1136/bmjopen-2022-071277

Ejemplares similares